|
1
|
Theodosopoulos PV and Pensak ML:
Contemporary management of acoustic neuromas. Laryngoscope.
121:1133–1137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou L, Zuo Z and Chow MS: Danshen: An
overview of its chemistry, pharmacology, pharmacokinetics, and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan GW, Gao XM, Wang H, Zhu Y, Zhang J, Hu
LM, Su YF, Kang LY and Zhang BL: The anti-inflammatory activities
of Tanshinone IIA, an active component of TCM, are mediated by
estrogen receptor activation and inhibition of iNOS. J Steroid
Biochem Mol Biol. 113:275–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang AM, Sha SH, Lesniak W and Schacht J:
Tanshinone (Salviae miltiorrhizae extract) preparations attenuate
aminogly-coside-induced free radical formation in vitro and
ototoxicity in vivo. Antimicrob Agents Chemother. 47:1836–1841.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong Y, Morris-Natschke SL and Lee KH:
Biosynthesis, total syntheses, and antitumor activity of
tanshinones and their analogs as potential therapeutic agents. Nat
Prod Rep. 28:529–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
|
|
7
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
8
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poon E, Harris AL and Ashcroft M:
Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
Expert Rev Mol Med. 11:e262009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sughrue ME, Yeung AH, Rutkowski MJ, Cheung
SW and Parsa AT: Molecular biology of familial and sporadic
vestibular schwannomas: Implications for novel therapeutics. J
Neurosurg. 114:359–366. 2011. View Article : Google Scholar
|
|
11
|
Aggarwal BB and Shishodia S: Molecular
targets of dietary agents for prevention and therapy of cancer.
Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang
J and Wang W: Potential anticancer activity of tanshinone IIA
against human breast cancer. Int J Cancer. 116:799–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu JJ, Lin DJ, Liu PQ, Huang M, Li XD and
Huang RW: Induction of apoptosis and inhibition of cell adhesive
and invasive effects by tanshinone IIA in acute promyelocytic
leukemia cells in vitro. J Biomed Sci. 13:813–823. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiu TL and Su CC: Tanshinone IIA induces
apoptosis in human lung cancer A549 cells through the induction of
reactive oxygen species and decreasing the mitochondrial membrane
potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
|
|
15
|
Su CC, Chen GW and Lin JG: Growth
inhibition and apoptosis induction by tanshinone I in human colon
cancer Colo 205 cells. Int J Mol Med. 22:613–618. 2008.PubMed/NCBI
|
|
16
|
Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF
and Zhang J: Growth inhibition and apoptosis induction of
tanshinone II-A on human hepatocellular carcinoma cells. World J
Gastroenterol. 10:2024–2028. 2004.PubMed/NCBI
|
|
17
|
Semenza GL: HIF-1 and tumor progression:
Pathophysiology and therapeutics. Trends Mol Med. 8(4 Suppl):
S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagle DG and Zhou YD: Natural
product-based inhibitors of hypoxia-inducible factor 1 (HIF-1).
Curr Drug Targets. 7:355–369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu M, Cao F, Liu L, Zhang B, Wang Y, Dong
H, Cui Y, Dong M, Xu D, Liu Y, et al: Tanshinone IIA-induced
attenuation of lung injury in endotoxemic mice is associated with
reduction of hypoxia-inducible factor 1vα expression. Am J Respir
Cell Mol Biol. 45:1028–1035. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Minet E, Michel G, Mottet D, Raes M and
Michiels C: Transduction pathways involved in Hypoxia-Inducible
Factor-1 phosphorylation and activation. Free Radic Biol Med.
31:847–855. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia Y, Choi HK and Lee K: Recent advances
in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem.
49:24–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Melillo G: Targeting hypoxia cell
signaling for cancer therapy. Cancer metastasis Rev. 26:341–352.
2007. View Article : Google Scholar : PubMed/NCBI
|
